Abstracts

SARS-CoV-2 PERSISTS IN INTESTINAL ENTEROCYTES UP TO 7 MONTHS AFTER SYMPTOM RESOLUTION

Host proteins ACE-2 and TMPRSS2 facilitate SARS-COV-2 infection and are expressed in the lungs as well as the intestinal tract, particularly in the small bowel. Gastrointestinal symptoms represent the most common extrapulmonary manifestation of COVID-19. Viral RNA has been isolated from fecal samples from COVID-19 patients, where it can persist longer than detection in nasopharyngeal…

BARICITINIB LOWERS INFLAMMATION AND PATHOLOGY IN SARS-CoV-2–INFECTED RHESUS MACAQUES

The emergence of SARS-CoV-2 and COVID-19 pandemic has placed an excessive burden on public and private healthcare systems with over 1,400,000 deaths worldwide. Thus, therapeutics aimed at mitigating disease severity are urgently needed. Immunological features of COVID-19 progression include an influx of innate and adaptive immune cells to the lung, with severe cases having elevated…

SARS-CoV-2 RECRUITS A HAEM METABOLITE TO EVADE ANTIBODY IMMUNITY

Understanding antibody immunity to SARS-CoV-2 and how the virus evades it is of critical importance in the fight against COVID-19. Our best hope of ending the pandemic is antibody-inducing vaccination, yet the precise targets and indeed protective capacity of antibodies remain incompletely defined. The coronaviral spike is the dominant viral antigen and the target of…

BAMLANIVIMAB PREVENTS COVID-19 MORBIDITY AND MORTALITY IN NURSING-HOME SETTING

The COVID-19 pandemic has disproportionately affected residents of skilled nursing and assisted living facilities. Interventions are urgently needed to protect this vulnerable population. Bamlanivimab is a potent neutralizing monoclonal antibody that binds the receptor-binding domain of the spike protein of SARS-CoV-2. This study evaluates the safety and efficacy of bamlanivimab in preventing COVID-19. BLAZE-2 is…

BAMLANIVIMAB+ETESEVIMAB FOR TREATMENT OF COVID-19 IN HIGH-RISK AMBULATORY PATIENTS

Patients with underlying medical conditions have a greater risk of developing severe COVID-19. Unlike vaccine-derived immunity which develops over time, administration of neutralizing monoclonal antibodies is an immediate, passive humoral immunotherapy, with the potential to reduce disease progression, emergency room visits, hospitalizations, and death. In this phase 3 portion of the BLAZE-1 trial, a high-risk…

POTENT NEUTRALIZING ANTIBODIES FOR SEVERE COVID-19: A RANDOMIZED CLINICAL TRIAL

Convalescent plasma could be an inexpensive and widely available drug for COVID-19 patients. Reports on its effectiveness are inconclusive. We collected convalescent plasma with high titers of neutralizing anti-SARS-CoV-2 antibodies effectively blocking SARS-CoV-2 infection and assessed their clinical and viro-immunological responses in COVID-19 patients with severe disease. In a multicentre open-label randomized clinical trial in…